Literature DB >> 35583706

External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort.

Elena Vissio1,2, Francesca Maletta3, Jessica Fissore1, Simona Osella Abate1, Francesca Retta4, Maria Pia Brizzi5, Alessandro Piovesan4, Ruth Rossetto Giaccherino6, Marco Volante7,8, Mauro Papotti1,8.   

Abstract

Medullary thyroid carcinoma (MTC) is a rare thyroid carcinoma with a variable clinical behavior. Potential clinical and pathological prognostic markers have been investigated, but studies are limited and controversial. In neuroendocrine neoplasms of various other sites, necrosis and proliferation (mitotic activity and/or Ki67 index) are integrated to provide a histological grade. Recently, an International Medullary Thyroid Carcinoma Grading System (IMTCGS) has been designed to define high- or low-grade MTC by combining proliferative activity and necrosis. This proposal integrates two previously published grading schemes by American (2-tiered grading, low- and high-grade MTC) and Australian authors (3-tiered grading, low-, intermediate-, and high-grade MTC). To validate the clinical role of these systems, their prognostic impact was evaluated in an independent cohort of 111 MTCs. Necrosis, which was the only parameter integrated into the 3 grading systems, proved to be individually correlate with tumor relapse, while no association was found with the proliferation (mitotic count and Ki67 index); however, by combining the different parameters according to all three grading systems, "high-grade" MTCs turned out to be significantly associated with the disease recurrence (p < 0.005) in all systems. In disease-free survival analysis, the IMTCGS stratification was the only one that demonstrated a significant impact at Cox regression analysis (p = 0.004), further confirmed by the Kaplan-Meier curves (p = 0.002). Similar findings were also reproduced when analysis was restricted to sporadic MTCs (68 cases). In conclusion, our results confirm the prognostic role of IMTCGS, supporting the importance of incorporating this information into the pathology report. However, none of the systems proved to predict the overall survival in this validation cohort.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Grading; Medullary thyroid carcinoma; Neuroendocrine carcinoma; Prognosis

Mesh:

Substances:

Year:  2022        PMID: 35583706     DOI: 10.1007/s12022-022-09719-z

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   4.056


  20 in total

1.  Medullary thyroid carcinoma: long-term outcomes of surgical treatment.

Authors:  Deepak T Abraham; Tsu-Hui Low; Marinella Messina; Nicole Jackson; Anthony Gill; Angela S Chou; Leigh Delbridge; Diana Learoyd; Bruce G Robinson; Stan Sidhu; Mark Sywak
Journal:  Ann Surg Oncol       Date:  2010-09-28       Impact factor: 5.344

Review 2.  Medullary thyroid carcinoma and biomarkers: past, present and future.

Authors:  W van Veelen; J W B de Groot; D S Acton; R M W Hofstra; J W M Höppener; T P Links; C J M Lips
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

3.  Medullary thyroid carcinoma: search for histological predictors of survival (109 proband cases analysis).

Authors:  B Franc; M Rosenberg-Bourgin; B Caillou; N Dutrieux-Berger; J Floquet; M Houcke-Lecomte; E Justrabo; F Lange; F Labat-Moleur; M F Le Bodic; M Patey; A Beauchet; J P Saint-André; G Hejblum; G Viennet
Journal:  Hum Pathol       Date:  1998-10       Impact factor: 3.466

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

5.  Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.

Authors:  Caterina Mian; Gianmaria Pennelli; Susi Barollo; Elisabetta Cavedon; Davide Nacamulli; Federica Vianello; Isabella Negro; Giulia Pozza; Isabella Merante Boschin; Maria Rosa Pelizzo; Massimo Rugge; Franco Mantero; Maria Elisa Girelli; Giuseppe Opocher
Journal:  Eur J Endocrinol       Date:  2011-03-21       Impact factor: 6.664

6.  Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma.

Authors:  A Ríos; J M Rodríguez; J M Acosta; M D Balsalobre; N Torregrosa; J Sola; D Pérez-Flores; P Parrilla
Journal:  Ann Surg Oncol       Date:  2010-03-12       Impact factor: 5.344

Review 7.  RAS proto-oncogene in medullary thyroid carcinoma.

Authors:  Margarida M Moura; Branca M Cavaco; Valeriano Leite
Journal:  Endocr Relat Cancer       Date:  2015-10       Impact factor: 5.678

8.  Prognostic and predictive markers in medullary thyroid carcinoma.

Authors:  Boban M Erovic; Dae Kim; Clarissa Cassol; David P Goldstein; Jonathan C Irish; Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

9.  Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register.

Authors:  F Raue; J Kotzerke; D Reinwein; S Schröder; H D Röher; H Deckart; R Höfer; M Ritter; F Seif; H Buhr
Journal:  Clin Investig       Date:  1993-01

10.  Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Authors:  Rossella Elisei; Barbara Cosci; Cristina Romei; Valeria Bottici; Giulia Renzini; Eleonora Molinaro; Laura Agate; Agnese Vivaldi; Pinuccia Faviana; Fulvio Basolo; Paolo Miccoli; Piero Berti; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.